{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T07:10:35.119451+00:00","company":{"ticker":"LRMR","cik":1374690,"company_name":"Larimar Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"25602a819e37cb7f08abf1961a3161fd8a61b83a","cik":1374690,"ticker":"LRMR","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"J.P. Morgan Securities LLC and Guggenheim Securities, LLC","effective_date":"2026-02-25","item_codes_triggered":["1.01"],"value_text":"20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds"},"claim":"Larimar Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Guggenheim Securities, LLC valued at 20,000,000 shares at $5.00 per share, option for additional 3,000,000 shares exercised, net proceeds (effective 2026-02-25).","evidence_excerpt":"On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company at a public offering price of $5.00 per share (the “ Offering ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-077646","anchor_url":"https://secwatch.observer/filing/0001193125-26-077646#claim-25602a819e37cb7f08abf1961a3161fd8a61b83a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526077646/0001193125-26-077646-index.htm"},{"fact_type":"earnings_release","fact_key":"641fb18e21cea127964ea13c8542a806e84cd2e0","cik":1374690,"ticker":"LRMR","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.27 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$14.7 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Larimar Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $14.7 million, EPS $0.27 per share.","evidence_excerpt":"The Company reported a net loss for the first quarter of 2024 of $14.7 million, or $0.27 per share, compared to a net loss of $6.5 million, or $0.15 per share, for the first quarter of 2023.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0000950170-24-056248","anchor_url":"https://secwatch.observer/filing/0000950170-24-056248#claim-641fb18e21cea127964ea13c8542a806e84cd2e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024056248/0000950170-24-056248-index.htm"}]}